Table 2.

CNS-Active Medication Use and Risk of Fall-Related Injury

CNS Medication Use	Primary Analysis					Sensitivity Analysis†,‡
	Person-Years	Fall-Related Injury	Fall-Related Injury Rate (per 100 person-years)	Adjusted Model* ,†
				HR	95% CI	HR	95% CI
None	10,986	386	3.5	1.00	Reference	1.00	Reference
Past	2,162	88	4.1	1.15	(0.91–1.45)	1.19	(0.87–1.64)
Recent	754	29	3.8	1.07	(0.73–1.57)	1.08	(0.65–1.81)
Current use	1,629	121	7.4	1.95	(1.57–2.42)	1.86	(1.38–2.50)
According to SDD
<1	476	33	6.9	1.73	(1.20–2.48)	1.17	(0.66–2.07)
1–<2	531	52	9.8	2.60	(1.93–3.51)	2.72	(1.83–4.04)
≥2	622	36	5.8	1.56	(1.10–2.22)	1.72	(1.10–2.67)

Note: SDD = standardized daily dose; HR = hazard ratio; CI = confidence interval.

*Results for primary outcome of fall-related injury resulting in ED or outpatient visit or hospitalization.

^†Adjusted for age, sex, ACT study cohort, and time varying measures of body mass index, self-rated health, hypertension, diabetes, stroke, urinary incontinence, osteoarthritis, coronary artery disease, congestive heart failure, Parkinson’s disease, gait speed, depressive symptoms, impaired cognition, and poor vision.

^‡Adjusted HR for the outcome of fall-related injury resulting in ED visit or hospitalization.